14,15-Epoxyeicosa-5( Z )-enoic Acid
- 17 May 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 90 (9), 1028-1036
- https://doi.org/10.1161/01.res.0000018162.87285.f8
Abstract
Endothelium-dependent hyperpolarization and relaxation of vascular smooth muscle are mediated by endothelium-derived hyperpolarizing factors (EDHFs). EDHF candidates include cytochrome P-450 metabolites of arachidonic acid, K+, hydrogen peroxide, or electrical coupling through gap junctions. In bovine coronary arteries, epoxyeicosatrienoic acids (EETs) appear to function as EDHFs. A 14,15-EET analogue, 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) was synthesized and identified as an EET-specific antagonist. In bovine coronary arterial rings preconstricted with U46619, 14,15-EET, 11,12-EET, 8,9-EET, and 5,6-EET induced concentration-related relaxations. Preincubation of the arterial rings with 14,15-EEZE (10 μmol/L) inhibited the relaxations to 14,15-EET, 11,12-EET, 8,9-EET, and 5,6-EET but was most effective in inhibiting 14,15-EET–induced relaxations. 14,15-EEZE also inhibited indomethacin-resistant relaxations to methacholine and arachidonic acid and indomethacin-resistant and l-nitroarginine-resistant relaxations to bradykinin. It did not alter relaxation responses to sodium nitroprusside, iloprost, or the K+ channel activators (NS1619 and bimakalim). Additionally, in small bovine coronary arteries pretreated with indomethacin and l-nitroarginine and preconstricted with U46619, 14,15-EEZE (3 μmol/L) inhibited bradykinin (10 nmol/L)–induced smooth muscle hyperpolarizations and relaxations. In rat renal microsomes, 14,15-EEZE (10 μmol/L) did not decrease EET synthesis and did not alter 20-hydroxyeicosatetraenoic acid synthesis. This analogue acts as an EET antagonist by inhibiting the following: (1) EET-induced relaxations, (2) the EDHF component of methacholine-induced, bradykinin-induced, and arachidonic acid–induced relaxations, and (3) the smooth muscle hyperpolarization response to bradykinin. Thus, a distinct molecular structure is required for EET activity, and alteration of this structure modifies agonist and antagonist activity. These findings support a role of EETs as EDHFs.Keywords
This publication has 36 references indexed in Scilit:
- Mechanism and signal transduction of 14 (R), 15 (S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytesProstaglandins & Other Lipid Mediators, 2000
- Role of gap junctions and EETs in endothelium-dependent hyperpolarization of porcine coronary arteryBritish Journal of Pharmacology, 2000
- P450 SUBFAMILY CYP2J AND THEIR ROLE IN THE BIOACTIVATION OF ARACHIDONIC ACID IN EXTRAHEPATIC TISSUES*Drug Metabolism Reviews, 1999
- High Affinity Binding Sites for 12(R)-Hydroxyeicosatrienoic Acid [12(R)-HETrE] in Microvessel Endothelial CellsJournal of Ocular Pharmacology and Therapeutics, 1997
- Evidence Against the Involvement of Cytochrome P450 Metabolites in Endothelium‐Dependent Hyperpolarization of the Rat Main Mesenteric ArteryThe Journal of Physiology, 1997
- Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cellsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Human Umbilical Vein Endothelial Cells Express P450 2C8 mRNA: Cloning of Endothelial P450 EpoxygenaseEndothelium, 1996
- Role of Cytochrome P-450 Enzymes and Metabolites of Arachidonic Acid in the Control of Vascular ToneJournal of Vascular Research, 1995
- Arachidonate epoxygenase: inhibitors and metabolite analoguesTetrahedron Letters, 1985
- Selective epoxidation of eicosa-cis-5,8,11,14-tetraenoic (arachidonic) acid and eicosa-cis-8,11,14-trienoic acidJournal of the American Chemical Society, 1979